Delusion

• Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development.
• Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia.
• “Liz is a preeminent drug research and development leader with extensive experience in the advancement and commercialization of first in class therapies,” said Steve Davis, Chief Executive Officer.
• She joined Horizon in 2018 and served in roles of increasing responsibility that culminated at Executive Vice President, Research and Development.

• All you need is love.
• It’s better to have loved and lost than never to have loved at all.
• But is love all pink hearts, roses and teddy bears – or is there a darker side?

Pathological Love

• Love can hurt.
• Ian McEwan framed a pathological form of affection, leading to obsession in his 1997 novel “Enduring Love”.
• They appear even in the words of Hippocrates, described as a form of unrequited love.
• The condition has seen a renaissance, over the past three centuries, shifting from unanswered love to sex addiction, to its current standing of delusions of love.

I love Paris in the springtime

• Love, or perceptions of love for material objects or places rather than individuals might also be enough to trigger psychiatric illness.
• Stendhal was not a psychiatrist, but a writer, who found himself overcome by the beauty of Florence when travelling there in 1817.
• For others, unfortunately not – leading to a condition known as Paris Syndrome.

Too many broken hearts in the world

• The term broken heart syndrome applies to a genuine cardiac condition – Takotsubo cardiomyopathy.
• The underlying cause of broken heart syndrome?
• The raised levels of adrenaline have been proposed as an underlying cause of broken heart syndrome – a link between heart and mind – though more research is required to tell for sure.

Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

• Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
• For more information on the Waldencast investigation go to: https://bespc.com/cases/WALD
  On November 16, 2023, Viceroy Research released a report entitled "Arbor Realty Trust - Slumlord Millionaires."
• In this report, Viceroy stated that it "[i]nvestors in bridge financing underwriters and their portfolios of loans appear to be [.
• In addition, according to the order, Brooge agreed during the SEC’s investigation not to issue the $500 million in securities.

• ANAVEX®3-71 positive initial Phase 1 results in healthy volunteers were previously reported.1
  ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects.
• As currently approved treatments only control a subset of symptoms, patients continue to exhibit severe impairments in social and occupational functioning and poor quality of life.
• The placebo-controlled Phase 2 ANAVEX®3-71-SZ-001 study, will consist of two-parts to explore multiple ascending doses in individuals with schizophrenia followed by a 28-day treatment period in a larger cohort.
• While current antipsychotic therapies can be effective in managing positive symptoms, like hallucinations and delusions, they may not fully address persistent negative symptoms or cognitive difficulties.